Firhan leads financial activities and operations at Proteorex. Firhan brings broad experience in, and knowledge of, the pharmaceutical, biotechnology, and investment industries to the team.
Previously, Firhan was a Senior Associate at Willow Tree Capital Group, a boutique healthcare consulting firm. At Willow Tree, Firhan helped clients identify and execute opportunities for growing their business (e.g., licensing/partnering of a drug or technology, M&As), conducted business development and marketing activities, and developed investor presentations. He led the due diligence process at Willow Tree as part of a major endeavour, which resulted in the acquisition of the Clozaril® (schizophrenia) drug from Novartis, on behalf of HLS Therapeutics, a specialty pharmaceutical company and Willow Tree strategic advisory client.
Firhan obtained his PhD in physiology from the University of Toronto. He primarily studied cystic fibrosis, a rare genetic disease, and congestive heart failure in the renowned medical research institutions the Hospital for Sick Children, the Heart and Stroke Richard Lewar Center in Excellence, and the MaRS Discovery District. Firhan also has a MSc. in biochemistry from the University of Toronto and a Hon. BSc. in biochemistry from Laurentian University. His research work was funded by the Natural Sciences and Engineering Research Council (NSERC) of Canada.